Company Overview and News
Aralez's Q3 announced positive Adjusted EBITDA for first time with updated 2017 net revenues guidance in the $95M to $105M range. (97-0)
The following slide deck was published by Aralez Pharmaceuticals Inc. in conjunction with their 2017 Q3 earnings call. (62-0)
Greetings, and welcome to the Aralez Pharmaceuticals Third Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (62-0)
Aralez has previously given guidance that it will generate $80M to $100M in annual sales in 2017 with estimated EBIDTA between ($5M) to $5M Q3 2017 earnings release scheduled for. (62-0)
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (578-4)
TORONTO, ONTARIO--(Marketwired - Oct. 3, 2017) - Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company") is pleased to announce the appointment of Scott Langille as the Company's Chief Financial Officer effective October 2, 2017, subject to regulatory approval. (62-1)
Shares have nearly doubled in the past month, but still have room to rise higher in order to fill the gap. (87-1)
AstraZeneca, plc (AZN - Free Report) announced that it has entered into an agreement to dispose theremaining rights to its anaesthetics medicines, to Aspen Global Incorporated (AGI), the Mauritian subsidiary of the Aspen Group, for an upfront consideration of $555 million. (4-1)
Greetings, and welcome to the Aralez Pharmaceuticals Second Quarter 2017 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Adrian Adams, Chief Executive Officer of Aralez Pharmaceuticals. Thank you, Mr. Adams. You may begin. (0-1)
Weighing both the pros and cons, this looks like a cautious investment with a small stake to begin with. (0-1)
MISSISSAUGA, Ontario, July 24, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its second quarter 2017 financial results on Wednesday, August 9, 2017, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 9:00 a.m. ET on such date to discuss the Company's financial results, provide a business update and will address questions from analysts.
We’re interviewing an interventional cardiologist whose research focuses on defining the effects of antiplatelet agents, antiplatelet agent development, and understanding the relation of platelet reactivity to ischemic event occurrence.
Biotech stalwart Celgene continues to make significant collaboration deals throughout the industry across myriad disease areas. (0-1)
As well, Yosprala sales have improved following recent marketing and pricing strategy changes, but remain a question mark.
As the offspring of Pozen and Tribute Pharmaceuticals, Aralez has performed very poorly over the past year (down 80% from its one-year high).
Stock Research Report
Aralez is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Its parent corporation, Aralez Pharmaceuticals Inc., was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on December 2, 2015. its global headquarters is located in Mississauga, Ontario, Canada, its U.S. headquarters is located in Princeton, New Jersey, United States, and its Irish headquarters is located in Dublin, Ireland. Aralez was formed for the purpose of facilitating the business combination of POZEN Inc., a Delaware corporation (“Pozen”), and Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (“Tribute”), which transaction closed on February 5, 2016.
On February 5, 2016, pursuant to an Agreement and Plan of Merger and Arr...
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton